Skip to Content

Neupro Side Effects

Generic Name: rotigotine

Note: This document contains side effect information about rotigotine. Some of the dosage forms listed on this page may not apply to the brand name Neupro.

For the Consumer

Applies to rotigotine: transdermal patch extended release

Along with its needed effects, rotigotine (the active ingredient contained in Neupro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking rotigotine:

More common
  • Burning, itching, redness, skin rash, swelling, or soreness at the application site
  • swelling of the hands, ankles, feet, or lower legs
Less common
  • Bladder pain
  • bloody or cloudy urine
  • blurred vision or other changes in vision
  • difficult, burning, or painful urination
  • dizziness
  • frequent urge to urinate
  • headache
  • lower back or side pain
  • nervousness
  • pounding in the ears
  • seeing, hearing, or feeling things that are not there
  • slow or fast heartbeat

Get emergency help immediately if any of the following symptoms of overdose occur while taking rotigotine:

Symptoms of overdose
  • Confusion
  • convulsions
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • nausea
  • sweating
  • unusual tiredness or weakness
  • vomiting

Some side effects of rotigotine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Sleepiness or unusual drowsiness
Less common
  • Acid or sour stomach
  • belching
  • difficulty having a bowel movement (stool)
  • difficulty with moving
  • dreaming abnormal
  • dry mouth
  • feeling of constant movement of self or surroundings
  • heartburn
  • indigestion
  • loss of appetite
  • muscle pain or stiffness
  • pain in the joints
  • sensation of spinning
  • sleeplessness
  • stomach discomfort, upset, or pain
  • trouble sleeping
  • unable to sleep
  • weight loss

For Healthcare Professionals

Applies to rotigotine: transdermal film extended release


Very common (10% or more): Peripheral edema (up to 14%), orthostatic hypotension (up to 32%)
Common (1% to 10%): Abnormal ECG T wave, first degree AV block, hypertension, palpitations
Uncommon (0.1% to 1%): Atrial fibrillation
Rare (less than 0.1%): Supraventricular tachycardia[Ref]

The incidence of significant decreases in blood pressure or orthostatic hypotension increased during periods of dose escalation and titration. In patients taking maximum recommended doses, orthostatic hypotension occurred (compared to placebo) at 29% (vs 11%), 27% (vs 23%), and 8% (vs 7%), in those with early stage Parkinson's disease (PD), advanced-stage PD, and restless legs syndrome, respectively.

The incidence of peripheral edema was 3% and 2% for patients with early-stage PD compared with 9% and 1% for patients with advanced-stage PD receiving drug and placebo, respectively.[Ref]


Very common (10% or more): Nausea (up to 41%), vomiting (up to 20%),
Common (1% to 10%): Dyspepsia, constipation, diarrhea, dry mouth,
Uncommon (0.1% to 1%): Abdominal pain[Ref]

Nausea and vomiting may occur at the beginning of therapy but these are usually mild or moderate in intensity and transient even if treatment is continued.[Ref]

Nervous system

Very common (10% or more): Somnolence (up to 32%), dizziness (up to 23%), dyskinesia (up to 14%), headache (up to 21%)
Common (1% to 10%): Balance disorder, paresthesia, tremor, hypoesthesia, sleep attacks
Rare (less than 0.1%): Convulsion[Ref]

In clinical trials, 2% of patients receiving maximum doses of this drug for restless legs syndrome reported sleep attacks compared with 0% of patients receiving placebo.[Ref]


Very common (10% or more): Arthralgia (up to 11%)
Common (1% to 10%): Muscle spasms
Frequency not reported: Elevated creatine phosphokinase[Ref]


Common (1% to 10%): Sinus congestion, nasal congestion, cough, nasopharyngitis, hiccups[Ref]


Common (1% to 10%): Visual disturbances
Uncommon (0.1% to 1%): Blurred vision, visual impairment, photopsia[Ref]


Common (1% to 10%): WBC in urine
Uncommon (0.1% to 1%): Erectile dysfunction[Ref]


Common (1% to 10%): Hypersensitivity including tongue edema and lip edema[Ref]


Uncommon (0.1% to 1%): Hepatic enzyme increases (ALT, AST, GGT)[Ref]


Common (1% to 10%): Anorexia, increased weight, decreased weight
Frequency not reported: Decreased serum glucose[Ref]


Frequency not reported: Elevated BUN[Ref]


Common (1% to 10%): Decreased serum ferritin
Frequency not reported: Decreased hemoglobin/hematocrit[Ref]


Very common (10% or more): Application site reactions (up to 46%), hyperhidrosis (up to 11%)
Common (1% to 10%): Erythema, pruritus,
Uncommon (0.1% to 1%): Contact dermatitis
Rare (less than 0.1%): Generalized rash[Ref]

Application site reactions (ASRs) exhibited a dose-dependent relationship for all doses in patients with both Parkinson's disease and restless legs syndrome. Reactions included localized erythema, edema, or pruritus, generally limited to the patch area; although generalized skin reactions such as allergic rash, including erythematous, macular-papular rash, or pruritus were reported at a lower incidence. Rotation of application sites has been shown to reduce the incidence of ASRs.

When applied as instructed, 34.2% (n=748) of patients experienced ASR; the majority were mild or moderate in intensity. Discontinuation occurred in 7.2% of patients[Ref]


Very common (10% or more): Disturbances in initiating and maintaining sleep (up to 14%), hallucinations (up to 13%)
Common (1% to 10%): Abnormal dreams, nightmare, irritability, sleep disorder, depression, impulse-control disorders
Uncommon (0.1% to 1%): Obsessive-compulsive disorder, disorientation, agitation
Rare (less than 0.1%): Aggressive behavior, binge eating, delusion, delirium[Ref]


Asthenic conditions included asthenia, malaise, and fatigue.[Ref]

Very common (10% or more): Fatigue (up to 18%), asthenic conditions (up to 14%)
Common (1% to 10%): Tinnitus, vertigo[Ref]


Common (1% to 10%): Menstrual disorder, sexual desire disorder[Ref]


The most common adverse reactions experienced among patients with Parkinson's disease included nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, disturbances in initiating and maintaining sleep, hyperhidrosis, visual disturbances, peripheral edema, and dyskinesia. For patients with Restless Legs Syndrome, the most common adverse reactions included application site reactions, nausea, disturbances in initiating and maintaining sleep, somnolence, and headache.[Ref]


Common (1% to 10%): Basal cell carcinoma[Ref]


1. "Product Information. Neupro (rotigotine)." Schwarz Pharma, Mequon, WI.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Some side effects of Neupro may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.